Michigan Medicine: Phase 1 Trial of Alrizomadlin Shows Promise in Targeting Metastatic Salivary Gland Cancers
May 13, 2026
May 13, 2026
ANN ARBOR, Michigan, May 13 (TNSjou) -- Michigan Medicine, the academic medical center of the University of Michigan, issued the following Q&A on May 12, 2026, involving Paul Swiecicki, clinical associate professor of Internal Medicine-Hematology/Oncology and member of the Rogel Cancer Center:
* * *
Phase 1 trial of alrizomadlin shows promise in targeting metastatic salivary gland cancers
Drug developed in U-M labs suggests potential new treatment optio . . .
* * *
Phase 1 trial of alrizomadlin shows promise in targeting metastatic salivary gland cancers
Drug developed in U-M labs suggests potential new treatment optio . . .